NOVN.SW Stock Today: February 05 — Q4 Sales Miss, Weak 2026 Outlook

Novartis stock is in focus today after Q4 sales missed expectations and management set a cautious 2026 outlook. The Basel group posted FY2025 profit of $17.4 billion, yet guided to low single-digit sales growth with a slight core EBIT decline next year, citing patent expiries and US pricing pressure. On the SIX, NOVN.SW slipped as investors weighed slowing momentum against strength in Cosentyx and Pluvicto. We explain the drivers, risks, valuation in CHF, and near-term catalysts for Swiss portfolios.

Q4 miss and 2026 outlook

Novartis flagged low single-digit sales growth in 2026 and a slight decline in core EBIT, attributing the softer view to patent expiries and US pricing. FY2025 profit reached $17.4 billion, according to Swiss media coverage, but the quarter fell short on revenue. Investors reacted to the slower growth path despite operational progress in key franchises. See coverage from SRF for highlights of the results source.

Consensus looked for firmer Q4 sales and a steadier 2026 margin profile. Management’s tone on pricing and patent pressure landed heavier than hoped, offsetting solid trends in Cosentyx and radioligand therapy. Local financial press noted the stock’s drop on the weaker outlook and top-line erosion. See the cash.ch recap of the market reaction source.

What moved the shares today

Novartis stock softened as investors marked down 2026 earnings power. Guidance implies slower revenue and a mild core EBIT decline as pricing and loss of exclusivity weigh. That backdrop eclipsed cost discipline and portfolio focus. The market often prices the next 12 months, so even small growth downgrades can shift multiples for a CHF blue-chip like Novartis.

Cosentyx remains a growth pillar, while Pluvicto expands in radioligand oncology. These helped steady trends, yet they could not fully counter the Q4 revenue miss. The question is whether 2026 launches and label expansions can bridge the gap to offset erosion elsewhere. For now, sentiment leans cautious until visibility improves.

Patent cliff and pipeline offset

The company faces a classic patent cliff as select brands near or enter generic and biosimilar competition. US price pressure compounds that risk. Management highlighted these forces in the 2026 outlook. For Swiss investors, the pace of erosion versus uptake in newer assets will set the revenue path and determine how quickly margins can stabilize.

Execution on growth drivers is key. Uptake in radioligand therapies, immunology, and cardiovascular assets can soften the patent hit. Investors should track trial readouts, approvals, and market access updates through 2026. If new products scale faster than expected, Novartis stock could re-rate toward prior highs even with ongoing pricing pressure.

Valuation, dividend, and technicals

On trailing metrics, the shares trade near a 20.7x P/E and a price-to-sales around 5.2, with a dividend yield near 2.95 percent and a payout ratio of roughly 54 percent. Balance-sheet quality looks solid with net debt to EBITDA near 1.0x and interest coverage around 15.7x. That supports the dividend while the company navigates 2026.

Short-term signals screen overbought, with RSI around 74 and multiple momentum oscillators elevated. That can cap upside until new catalysts arrive or the shares consolidate. For CHF buyers, staggered entries and focus on support levels may help manage risk. Our Stock Grade stands at B+ with a Buy suggestion, reflecting solid fundamentals.

The next earnings date is 27 April 2026, which should refine guidance and margin talk. Monitor pricing commentary in the US, loss-of-exclusivity updates, and uptake in Cosentyx and Pluvicto. FX and capital allocation will matter for CHF returns. Any acceleration in the pipeline could shift the 2026 narrative and aid a re-rating.

Final Thoughts

Novartis stock slipped after a Q4 revenue miss and a cautious 2026 guide that calls for low single-digit sales growth and a slight core EBIT decline. The drag comes from patent expiries and US pricing. Offsetting forces include strong franchises like Cosentyx and Pluvicto, healthy cash generation, and a near 3 percent dividend yield supported by solid coverage. For Swiss investors, the playbook is clear: watch product launch momentum, pricing color, and margin discipline into the 27 April earnings update. Consider phased buying given overbought technicals and keep an eye on support levels if volatility rises.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.